- British scientists behind the trial believe it will ‘transform’ treatment
- Some 46,500 men are diagnosed with prostate cancer in the UK every year
- Research was unveiled at American Society for Clinical Oncology conference
Sophie Borland Health Editor In Chicago For The Daily Mail
1
View
comments
Thousands of men could benefit from a new way of treating prostate cancer that doubles their average life expectancy, research has found.
Giving patients a combination of two drugs makes them nearly 40 per cent more likely to be alive after three years, the findings showed. British scientists behind the trial believe it will ‘transform’ prostate cancer treatment.
Currently, men with prostate cancer that has spread to surrounding tissue in the pelvic area are only given hormone therapy. This reduces the levels of the male hormones or ‘androgens’, which would otherwise fuel tumour growth.
Research found giving patients a combination of two drugs makes them nearly 40 per cent more likely to be alive after three years 9stock image)
But the research, unveiled at the American Society for Clinical Oncology conference in Chicago, found prescribing the drug abiraterone at the same time hugely improved the effectiveness of treatment.
Scientists from the University of Birmingham recruited 1,900 men with prostate cancer that had spread to their pelvic area or other organs. Of the 646 that died over three years, 262 had received just hormones, compared to only 184 who also received abiraterone. This represents an improved survival rate of 37 per cent.
If given both drugs, researchers believe a majority of the 15,000 men a year whose cancer spreads to the pelvic area would live the rest of their lives disease-free.
-
Dr Max: Why can’t doctors and nurses admit Tory NHS cuts are…
Pollution ‘sparks 10% rise in cancer cases’: Fumes thought…
If they were given to the 5,000 men with more advanced cancer, scientists predict average life expectancy would double from 3.5 years to at least seven. Birmingham University’s Professor Nicholas James, the chief investigator of the study, said: ‘These are the most powerful results I’ve seen from a prostate cancer trial.’
Approximately 46,500 men are diagnosed with prostate cancer in the UK every year. Around half are eligible for hormone therapy with abiraterone.
Dr Iain Frame, director of research at Prostate Cancer UK, said: ‘We will be working with all relevant bodies to make sure this treatment becomes an option available via the NHS.’
Share or comment on this article
- Arsenal jihadi ‘euphoric’ hours before murdering seven as…
- ‘Olivia wouldn’t want you to cry. She’d have wanted to…
- Family pay tribute to Canadian woman killed in terror…
- KATIE HOPKINS: You’re right, Theresa. We cannot go on…
- Armed police arrest 12 – including four women – at East…
- ‘Stay with me, please, I love you’: Bystanders rush to…
- Trump condemns London Mayor after terror attack:…
- Harrowing dashcam footage reveals trail of devastation on…
- Pippa Middleton and James Matthews return to civilisation…
- Hero neighbor shoots knife-wielding father dead as he…
- Body of Manchester terror victim Eilidh MacLeod, 14, is…
- ‘He’s a soldier’: Father-of-three stabbed FOUR times by…
- Desperate families beg for information on ‘missing’ loved…
- ISIS celebrates deaths of seven killed in London Bridge…
- Bystander caught in police crossfire was shot in the head…
- Where.Am.I? Bungling Black Eyed Pea Will.i.am slammed…
- ‘Bit of pain but I’ll survive’: Australian waitress, 31,…
- Another fanatic slips through the net: Killer jihadi, 27,…
Comments 1
Share what you think
-
Newest -
Oldest -
Best rated -
Worst rated
The comments below have not been moderated.
The views expressed in the contents above are those of our users and do not necessarily reflect the views of MailOnline.
Close
Your comment will be posted to MailOnline as usual.
Close
Your comment will be posted to MailOnline as usual
We will automatically post your comment and a link to the news story to your Facebook timeline at the same time it is posted on MailOnline. To do this we will link your MailOnline account with your Facebook account. We’ll ask you to confirm this for your first post to Facebook.
You can choose on each post whether you would like it to be posted to Facebook. Your details from Facebook will be used to provide you with tailored content, marketing and ads in line with our Privacy Policy.